|
|
|
1-10 employees
View all
|
|
Biotechnology
|
|
29, Rue du Faubourg Saint-Jacques, Paris, Île-de-France 75014, FR
|
|
PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology.
PEP-010, first drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile.
PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors.
PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.
|
PEP-Therapy Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used PEP-Therapy email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact PEP-Therapy customer service number in your country click here to find.
Antoine Prestat is the CEO of PEP-Therapy. To contact Antoine Prestat email at [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.